Silverarc Capital Management »

Macrogenics shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Macrogenics (MGNX) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Macrogenics

Tip: Access up to 7 years of quarterly data

All positions including Macrogenics held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Macrogenics by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $5.9M 1.3M 4.66
2023-06-30 $6.5M 1.2M 5.35
2023-03-31 $9.8M 1.4M 7.17
2022-12-31 $4.1M 613k 6.71
2022-09-30 $346k 100k 3.46
2021-06-30 $4.8M 177k 26.86

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Macrogenics

Bellevue Group
Vanguard Group
RA Capital Management
Frazier Life Sciences Management
Dimensional Fund Advisors
Jpmorgan Chase & Co
Daniel D. Thurber
Millennium Management
Charles Schwab Investment Management
Federated Investors
Gail Mannix
Goldman Sachs Group
Perceptive Advisors
PanAgora Asset Management
Principal Financial Group

View all funds holding Macrogenics